血清干扰素诱导蛋白评分对系统性硬化相关间质性肺病治疗反应的预测意义
本研究基于硬皮病肺研究II(SLS II)随机对照试验及独立观察队列,评估由6种干扰素诱导蛋白组成的复合评分对系统性硬化相关间质性肺病(SSc-ILD)免疫抑制治疗反应的预测价值。结果显示,基线干扰素诱导蛋白评分较高者接受霉酚酸酯(MMF)或环磷酰胺(CYC)治疗后肺功能改善更佳,而基线C反应蛋白(CRP)较高则预测更差的疾病进程。该评分有望用于识别最可能从MMF或CYC治疗中获益的患者。
要点
- 基线干扰素诱导蛋白评分较高预测MMF和CYC治疗3至12个月肺功能反应更好。
- 基线CRP较高预测两种治疗下ILD病程更差。
- 12个月时干扰素诱导蛋白评分较高在CYC转安慰剂后呈预测更差病程的趋势。
核心结论
- SSc-ILD患者中较高的干扰素诱导蛋白评分预测对免疫抑制治疗(MMF或CYC)有更好的反应。
- 该评分可能有助于识别最可能从MMF或CYC治疗中获益的患者。
研究设计与样本
- 研究样本来自硬皮病肺研究II(SLS II),一项比较霉酚酸酯(MMF)与环磷酰胺(CYC)的随机对照试验。
- 结果在独立观察队列(接受积极治疗)中进行验证。
- 计算由6种干扰素诱导蛋白组成的复合评分,评估其对纵向用力肺活量占预计值百分比(FVC% predicted)的预测意义。
主要发现
- 基线干扰素诱导蛋白评分较高预测MMF组3至12个月反应更好(点估计=0.41,P=0.001)。
- 基线干扰素诱导蛋白评分较高预测CYC组3至12个月反应更好(点估计=0.91,P=0.009)。
- 基线CRP较高预测两种治疗组ILD病程更差。
- 调整基线人口学和临床预测因素后,干扰素诱导蛋白评分和CRP的预测意义仍存在。
- 治疗第二年(CYC组转为安慰剂),12个月时干扰素诱导蛋白评分较高呈预测更差ILD病程的趋势(点估计=-0.61,P=0.068),而在MMF组仍预测对积极免疫抑制反应更好(点估计=0.28,P=0.029)。
关键数值与推荐
- 复合评分包含6种干扰素诱导蛋白:IFNγ诱导10-kd蛋白、IFNγ诱导单核因子、单核细胞趋化蛋白2、β2微球蛋白、肿瘤坏死因子受体II型、巨噬细胞炎症蛋白3β。
- MMF组基线干扰素诱导蛋白评分预测3至12个月FVC% predicted变化的点估计=0.41,P=0.001。
- CYC组基线干扰素诱导蛋白评分预测3至12个月FVC% predicted变化的点估计=0.91,P=0.009。
- CYC组转为安慰剂后12个月干扰素诱导蛋白评分预测更差ILD病程的点估计=-0.61,P=0.068。
- MMF组12个月干扰素诱导蛋白评分预测更好反应的点估计=0.28,P=0.029。
临床怎么用
- 基线血清干扰素诱导蛋白评分较高可提示SSc-ILD患者更可能从MMF或CYC治疗中获得肺功能改善。
- 基线CRP较高提示SSc-ILD患者ILD病程可能更差,需更密切监测。
- 该评分可能辅助临床决策,优先为高评分患者选择MMF或CYC免疫抑制治疗。
局限性
- 研究结果主要基于SLS II随机对照试验的事后分析,需进一步前瞻性验证。
- 独立验证队列为观察性设计,可能存在混杂因素。
- 干扰素诱导蛋白评分在CYC转为安慰剂后预测更差病程仅为趋势(P=0.068),未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Response to immunosuppression is highly variable in systemic sclerosis (SSc)-related interstitial lung disease (ILD). This study was undertaken to determine whether a composite serum interferon (IFN)-inducible protein score exhibits predictive significance for the response to immunosuppression in SSc-ILD. METHODS: Serum samples collected in the Scleroderma Lung Study II, a randomized controlled trial of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC), were examined. Results were validated in an independent observational cohort receiving active treatment. A composite score of 6 IFN-inducible proteins IFNγ-inducible 10-kd protein, monokine induced by IFNγ, monocyte chemotactic protein 2, β2 -microglobulin, tumor necrosis factor receptor type II, and macrophage inflammatory protein 3β) was calculated, and its predictive significance for longitudinal forced vital capacity percent predicted measurements was evaluated. RESULTS: Higher baseline IFN-inducible protein score predicted better response over 3 to 12 months in the MMF arm (point estimate = 0.41, P = 0.001) and CYC arm (point estimate = 0.91, P = 0.009). In contrast, higher baseline C-reactive protein (CRP) levels were predictive of a worse ILD course in both treatment arms. The predictive significance of the IFN-inducible protein score and CRP levels remained after adjustment for baseline demographic and clinical predictors. During the second year of treatment, in which patients in the CYC arm were switched to placebo, a higher IFN-inducible protein score at 12 months showed a trend toward predicting a worse ILD course (point estimate = -0.61, P = 0.068), while it remained predictive of better response to active immunosuppression in the MMF arm (point estimate = 0.28, P = 0.029). The predictive significance of baseline IFN-inducible protein score was replicated in the independent cohort (rs = 0.43, P = 0.028). CONCLUSION: A higher IFN-inducible protein score in SSc-ILD is predictive of better response to immunosuppression and could potentially be used to identify patients who may derive the most benefit from MMF or CYC.
引用
- Assassi S, Li N, Volkmann ER, et al. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol. 2021. PMID: 33350170. doi:10.1002/art.41627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。